BMJ Open · Nov 18, 2026
Feasibility and acceptability of high-intensity interval training for apathy after deep brain stimulation in Parkinson’s disease: the HIIT-ing apathy study protocol
By Musch K, Beudel M, Gravesteijn AS et al.
Introduction Apathy is a common and disabling non-motor symptom after subthalamic nucleus deep brain stimulation (STN-DBS) in persons with Parkinson’s disease (PwP), impairing daily functioning and quality of life (QoL) of both PwP and their caregivers. Pharmacological and stimulation-based treatments are often insufficient, highlighting the need for complementary non-pharmacological approaches such as physical exercise. In the outpatient rehabilitation clinic of Amsterdam University Medical Center (UMC), high-intensity interval training (HIIT) is part of routine rehabilitation due to its time efficiency, safety, tolerability and multiple health benefits. However, its feasibility and acceptability in PwP with apathy following STN-DBS have not been well explored, and its clinical effects are unknown. This pilot study therefore primarily aims to determine the feasibility, acceptability and safety of a structured HIIT programme targeting apathy in PwP following STN-DBS. Clinical outcomes will be assessed on an exploratory basis to inform the potential design of a future randomised controlled trial. Methods and analysis A patient and public involvement approach, engaging clinicians, researchers, a patient-researcher and a PwP, informed the development of a protocol for a single-centre, open-label pilot feasibility study. The study will include 10 PwP with clinically relevant apathy (Starkstein Apathy Scale ≥14) following STN-DBS, who will complete an 8-week HIIT programme comprising two physiotherapist-supervised cycle ergometer sessions per week. The target intensity corresponds to a Borg rating of perceived exertion of ≥15 during high-intensity intervals, recorded at the end of each interval. Primary outcomes are feasibility (eg, recruitment and retention), acceptability (eg, tolerability and participant burden) and safety (adverse events and unintended effects), which will be analysed descriptively. As the study is not powered for hypothesis testing, clinical outcomes—including apathy severity, QoL, motor and non-motor symptoms, functioning, activities of daily living, mood and anxiety, fatigue and caregiver burden—are exploratory and will be assessed using pre–post analyses to estimate effect sizes, which will inform the sample size calculation for a future randomised controlled trial. Ethics and dissemination This ongoing study is in accordance with the Declaration of Helsinki. The non-WMO Committee of the Medical Ethics Review Committee of Amsterdam UMC judged that the Dutch Medical Research Involving Human Subjects Act (WMO) does not apply, as participants are not subjected to procedures or required to follow rules of behaviour as defined by this Act, and therefore waived formal ethical approval (reference 2024.0155). All participants and their caregivers will provide written informed consent prior to participation.